申请人:Boehringer Ingelheim Pharma KG
公开号:US06087380A1
公开(公告)日:2000-07-11
New disubstituted bicyclic heterocycles of general formula R.sub.a --A--Het--B--Ar--E (I) Compounds of the above general formula I, wherein E denotes an R.sub.b NH--C(.dbd.NH)-- group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E denotes a cyano group, are valuable intermediates for preparing the other compounds of general formula I. Exemplary compounds of formula I are: (a) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide, (b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, (c) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl- carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, and (d) 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimid azol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl) amide.
通式为R.sub.a --A--Het--B--Ar--E (I)的新型二取代杂环化合物,其中E表示R.sub.b NH--C(.dbd.NH)--基团,具有有价值的药理学性质,特别是抑制凝血酶的作用和延长凝血酶时间的作用,其中E表示氰基的化合物是制备通式I其他化合物的有价值的中间体。通式I的示例化合物包括:(a) 1-甲基-2-[N-(4-胍基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-苯基-N-(2-羟基羧乙基)-酰胺,(b) 1-甲基-2-[N-(4-胍基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基甲基)-酰胺,(c) 1-甲基-2-[N-(4-胍基-2-甲氧基苯基)-氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(羟基甲基)-酰胺,以及(d) 1-甲基-2-[N-[4-(N-正己氧羰基胍基)苯基]氨甲基]-苯并咪唑-5-基-羧酸-N-(2-吡啶基)-N-(2-乙氧羰基乙基)酰胺。